Language:

Two year result of intravitreal bevacizumab for diabetic macular edema using treat and extend protocol

Medicine (Baltimore), 2017-04, Vol.96 (16), p.e6406-e6406 [Peer Reviewed Journal]

Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. 2017 ;ISSN: 0025-7974 ;EISSN: 1536-5964 ;DOI: 10.1097/md.0000000000006406 ;PMID: 28422832

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Two year result of intravitreal bevacizumab for diabetic macular edema using treat and extend protocol
Author: Sugimoto, Masahiko ; Ichio, Atsushi ; Nunome, Takayasu ; Kondo, Mineo
Subjects: Angiogenesis Inhibitors - administration & dosage ; Bevacizumab - administration & dosage ; Diabetic Retinopathy - diagnostic imaging ; Diabetic Retinopathy - drug therapy ; Female ; Follow-Up Studies ; Humans ; Intravitreal Injections ; Macular Edema - diagnostic imaging ; Macular Edema - drug therapy ; Male ; Middle Aged ; Observational Study ; Organ Size ; Prospective Studies ; Retrospective Studies ; Tomography, Optical Coherence ; Treatment Outcome
Is Part Of: Medicine (Baltimore), 2017-04, Vol.96 (16), p.e6406-e6406
Description: To determine the efficacy of the treat and extend (TAE) protocol with intravitreal bevacizumab (IVB) for managing diabetic macular edema (DME).Retrospective, single-center study.For this retrospective study, 42 eyes of 42 patients were initially treated with 3 consecutive monthly IVB injections (loading phase), after which they were selected for different additional therapies. For the TAE protocol, the baseline treatment interval was selected to be 8 weeks and was sequentially lengthened by 2 weeks if the central macular thickness (CMT) was <300 μm at 2 consecutive examinations.Among the 42 eyes, 8 eyes (19.0%) received the TAE treatment for 2 years. The BCVA was improved significantly from 0.37 ± 0.04 before treatment to 0.19 ± 0.04 logMAR units at 2 years after the TAE determined IVB injections (P < .05). The ratio of eyes with a gain of the BCVA by more than 2 lines was 37.5%. The CMT was significantly reduced from 515.4 ± 75.5 to 303.6 ± 45.0 μm after 2 years (P < .01). The mean number of TAE injection was 8.8 and the mean injection interval was 11.0 weeks.After the loading phase, 19.0% of patients can be treated with the TAE protocol. Although significant visual improvements were obtained after the TAE protocol, it does not apply to every DME case.
Publisher: United States: Wolters Kluwer Health
Language: English
Identifier: ISSN: 0025-7974
EISSN: 1536-5964
DOI: 10.1097/md.0000000000006406
PMID: 28422832
Source: IngentaConnect Open Access
Journals@Ovid Open Access Journal Collection Rolling
PubMed Central (Open access)
DOAJ Directory of Open Access Journals
MEDLINE
Wolters Kluwer Open Access

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Two year result of intravitreal bevacizumab for diabetic macular edema using treat and extend protocol

Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. 2017 ;ISSN: 0025-7974 ;EISSN: 1536-5964 ;DOI: 10.1097/md.0000000000006406 ;PMID: 28422832

Searching Remote Databases, Please Wait